Clinical trial CheckMate 8HW: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 8HW
A Phase 3b Randomized Clinical Trial of Nivolumab alone, Nivolumab in Combination with Ipilimumab, or an Investigator's Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer.
| Cancers | |
|---|---|
| Organ | Colon |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | BMS - Bristol Myers Squibb int. |
| EudraCT Identifier | 2018-000040-26 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT04008030 |
| Inclusion criteria | MSI high/Mismatch Repair Deficient |
| Last update |